Beacon Intelligence has launched Beacon Bispecific Patents, a new dataset designed to give drug development teams a clearer view of competitor IP and strategic direction in the fast-growing bispecific antibody field.

Built as part of the wider Beacon Patents platform, the bispecific dataset helps scientists, patent specialists and competitive intelligence teams move beyond keyword searches and dense legal language to understand who is filing what, where and why. The focus is on turning complex patent activity into practical insight that can guide R&D and business decisions with greater confidence.

From scattered filings to a joined-up competitor picture

Bispecific and multispecific antibodies are attracting intense investment, but the associated patent activity is fragmented across formats, mechanisms and jurisdictions. Traditional and AI-only patent tools often surface a high volume of loosely relevant documents, leaving users to manually piece together which competitors are active in their space and how those programmes are evolving.

Beacon Bispecific Patents has been created to close that gap. Using Beacon’s scientific ontologies, expert curation and trained AI models, the platform filters more than 100,000 bispecific-related patents to highlight filings that genuinely matter for innovators working with these modalities. Users can search by mechanism of action, molecular format, targets, disease indication and other bispecific-specific attributes to quickly pinpoint patents that overlap with their own strategies or signal new areas of interest.

Andy Cook, Chief Data Innovation Officer, at Beacon said: “Patent filings are often the earliest public sign of a competitor’s plans, but they are not easy to interpret at speed. Beacon Bispecific Patents has been built so that scientists and IP teams can see the bigger picture in minutes: who is moving into their space, how those assets are engineered and where there may be room to differentiate.”

Seeing who is gaining ground in the bispecific space

As part of the launch, Beacon has examined the behaviour of emerging players in the bispecific IP landscape. The exclusive “Emerging Bispecific Companies” chart (figure 1) included with this article shows the number of bispecific-related patents published in 2025 for a selection of companies.

Figure 1: Emerging Bispecific Companies

Graph showing Bispecific patent publications by select developers in 2025.

The data highlights a group of organizations that are rapidly increasing their activity in the field. With the exception of Broadwing Bio, all of the companies featured already appear on Beacon as developers in other modalities, underlining a broader strategic shift as firms extend their existing expertise into bispecific and multispecific platforms. This diversification provides a useful early signal of where competition may intensify and which partners or acquisition targets may become more attractive over time.

Beacon Bispecific Patents allows users to go beyond the headline chart and examine the underlying filings for each company, track changes in assignee, and follow how their patent families evolve. This supports more structured competitor monitoring, whether teams are assessing who is crowding a particular target class or mapping the engineering approaches that rivals are favouring.

Designed for competitor, IP and R&D teams

Beacon Bispecific Patents combines patent specialists with AI to cut down noise before results reach the user. Filings from over 100 patent offices are evaluated and summarised in clear technical language, with key claims and molecular features highlighted so that scientists can rapidly assess relevance.

Using the platform, teams can:

• Benchmark competitor portfolios by target, format, mechanism or disease area
• Identify potential infringement or overlap risks earlier in development
• Track how competitors enter new indications or move between technologies
• Spot white space where there is limited or no patent activity
• Export curated sets of patents for more detailed internal review

This level of structure means competitor intelligence teams are not starting from a blank page each time they assess a question. Instead, they can move straight to analysing patterns in filing behaviour and how those patterns align to broader portfolio strategy.

Andy Cook, Chief Data Innovation Officer, added: “Our customers are asking not just ‘what patents exist’, but ‘what does this tell us about our competitors and our own room to manoeuvre’. Beacon Bispecific Patents has been designed with that in mind. It gives a much clearer sense of where others are betting in the bispecific space and how secure those positions may be.”

Part of a broader patent intelligence platform

The bispecific dataset sits alongside Beacon’s ADC patent data , all accessible through a single interface. Together, they provide a joined-up view of patent activity across key therapeutic technologies, supported by the same ontologies, filters and summary approach that underpin Beacon’s drug, trial, company and deal datasets.

By bringing these sources together, Beacon aims to help users connect scientific innovation, IP strategy and commercial planning in a more coherent way. Patent activity can be viewed in context with clinical pipelines, company portfolios and partnering activity, offering a richer picture of how competitors are positioning themselves and where future opportunities may lie.

Find out more or request a demonstration for Beacon Bispecific Patents today!

Crescioli and Reichart set out to map and interpret how China’s biopharmaceutical sector is evolving in the domain of advanced antibody therapeutics, specifically with regards to Antibody-Drug Conjugates (ADCs) and Bispecific or Multispecific antibodies, over the past decade (2015-2024). Their goal was to contrast China’s trajectory with that of the more established antibody drug development ecosystems in the USA and Europe.

Key Findings:

• China has dramatically accelerated its capabilities in antibody-therapeutic innovation, using government-driven reform, investment, and streamlined regulatory processes as levers.
• Clinical-stage activity for enhanced antibodies in China now exceeds that in the USA and Europe, signaling a major shift in the global pipeline.
• Success rates for China-originated enhanced antibodies are reported to be markedly higher (57%) versus 15% for USA/Europe.
• The molecular formats being pursued differ: China is placing more emphasis on innovative bispecific ADCs and distinct payloads, such as topoisomerase I inhibitors rather than the DNA binders more common in the West.

The Importance of Beacon in Understanding the Global Antibody Therapeutic Landscape

Beacon ADC and Beacon Bispecific serve as sophisticated databases tracking the development, clinical progression, approvals and structural attributes of antibody-therapeutics globally.

Crescioli and Reichart utilized the Beacon ADC and Beacon Bispecific datasets within their research to ensure the accuracy and validity of their cross-geographical analyses. This highlights the importance of Beacon in enabling reliable, data-driven insights into the global landscape of therapeutic antibody development, supporting evidence-based comparisons across regions for researchers and developers.

The Beacon ADC and Beacon Bispecific Datasets Enable:

• Researchers and developers to quantify pipeline volumes, success/failure rates and format innovations in real-time.
• The segmentation by region (China vs USA/Europe) and therapeutic format (ADCs, bispecifics, bispecific-ADCs hybrid) of antibody therapeutics.
• An independent, data-driven foundation to commentary about who is “winning” in the antibody space and where the next breakthroughs may emerge.

Future Outlook

The authors conclude that China is on a path to potentially dominate the global enhanced antibody-therapeutics arena within the next five years, provided that manufacturing scale-up, regulatory harmonisation and global commercialisation challenges are effectively managed.

The fact that much of the current approval track record still belongs to the USA/Europe underscores that China must now convert its volume pipeline into approved products. Beacon’s continuing updates will likely help monitor this transition and flag when China-origin molecules begin capturing global market share.

For the broader ecosystem, this paper signals that stakeholders (investors, biotech firms, regulators) should recalibrate their view of where innovation is happening and prepare for a more distributed global competition in advanced antibodies.

Learn More About Beacon ADC and Beacon Bispecific

Beacon Intelligence has launched Beacon Neuroscience, a new database designed to help researchers, analysts, and decision-makers working in neuroscience drug development.

The database brings together curated data on more than 7,500 drugs and 9,000 clinical trials, offering a clear and structured view of innovation across the central nervous system (CNS) landscape. Developed with input from the scientific community, Beacon Neuroscience has been created to make it easier for professionals to find, analyze and act on the information that matters most.

A clearer picture of neuroscience development

Neuroscience remains one of the most complex areas of biomedical research. The field covers a broad range of conditions – from neurodegenerative and neuromuscular diseases to movement, genetic and cerebrovascular disorders – all of which are covered within the Beacon Neuroscience dataset.

Neuroscience continues to evolve rapidly with advances in drug discovery and delivery technologies and Beacon Neuroscience was developed to bring greater visibility to this activity.

The database enables users to explore drug and trial data in detail, helping them to identify emerging areas of research, track the progress of specific therapies and gain a better understanding of the wider development landscape.

All data within the database is manually curated and verified by Beacon’s in-house neuroscience team, ensuring accuracy and consistency across each record. The information is updated daily so users can be confident they are working with the latest data available.

Developed with scientists, for scientists

The creation of Beacon Neuroscience was guided by detailed feedback from researchers and R&D teams. The focus throughout has been on usability and providing tools that make it easier to interrogate large datasets, while maintaining the depth and precision that neuroscience professionals need.

Using the platform, users can:

• Compare drugs, mechanisms, and targets across multiple neuroscience disease indications
• Follow clinical trial activity and results in real time
• Identify potential collaborators or licensing opportunities
• Reduce time spent collecting and verifying data manually

Beacon’s structured ontologies and advanced search filters support more consistent and meaningful analysis, helping users to uncover patterns and insights that might otherwise remain hidden within complex datasets.

Designed to inform better decisions

By bringing together reliable, structured data in one place, Beacon Neuroscience aims to support faster and more informed decision-making across the sector.

Eloise Jarvis, Lead Research Analyst at Beacon, said:

“The neuroscience field is advancing quickly, but the amount of information available can make it difficult to keep track of what’s happening. Beacon Neuroscience gives drug developers a clear, accurate view of the data behind that progress. It’s been designed to help people explore confidently and draw their own conclusions.”

Building on Beacon’s existing expertise

Beacon Neuroscience joins a portfolio of therapeutic & disease databases developed by Beacon Intelligence, including oncology, ADC, cell therapy, and RNA therapeutics. Each database is built around the same principles: high-quality curation, transparent data, and user-led design.

As neuroscience research expands into new modalities and targets, Beacon plans to continue developing the platform, adding further layers of insight, including company and commercial data, as well as adding neuropsychiatric disorders including depression, anxiety, schizophrenia, and neurodevelopmental disorders to the dataset, to ensure it remains relevant and responsive to the needs of the community.

Find out more about how Beacon Neuroscience can accelerate your Neuroscience drug development decisions.

Patent literature is a valuable source of insight for drug developers, but it can be difficult to navigate. Traditional patent search tools often generate large volumes of irrelevant results, struggle with scientific terminology, and lack domain-aware filtering. Beacon ADC Patents addresses these challenges by applying scientific ontologies, expert curation, and advanced search methods to filter out noise and present high-impact patent data in a way that is usable and easy.

Bringing Clarity to a Booming ADC Patent Landscape

At its core, Beacon ADC Patents helps you reduce risk, uncover opportunities, and save time in your innovation workflow. Key features include:

• Expert-in-the-loop summaries that reduce false positives and highlight critical patent claims
• Modality-specific and technology search filters, enabling users to focus on relevant classes of inventions
• Cross-language patent translation, making patents filed in non-English jurisdictions accessible and usable
• Structured classification and ontology support, which allow consistent comparison across patents
• Global coverage, including translated Chinese patents and filings from key international authorities

Andy Cook, Chief Data Innovation Officer at Beacon said: “Beacon ADC Patents has been developed by scientists who understand how difficult it can be to extract value from traditional patent databases. Our platform suppresses the noise of false positives and makes it faster and easier for scientists to uncover relevant, high-impact patents that are critical to their R&D efforts. By presenting data in a clear, structured format, we’re helping users map competitor activity, identify potential risks, and explore new areas of innovation with confidence.”

Designed with Scientists in Mind

Beacon ADC Patents is built around the needs of patent analysts, researchers, and R&D teams who often spend significant time filtering through broad and inefficient patent databases. Beacon’s patent platform has been developed through consultation with domain experts to ensure it provides usability and granularity while maintaining scientific rigour.

With Beacon ADC Patents You Can:

• Apply filters by modality, therapeutic area, technology class, and patent events
• Read concise AI summaries with key chemical, biological, or molecular claims highlighted
• Compare related patent families and track filing histories
• Translate non-English filings into English where needed
• Export curated results for further review in internal workflows

By combining domain-aware ontologies and manual curation, Beacon ADC Patents supports deeper insight than generic patent databases.

Extending Beacon’s Data Ecosystem

Beacon Patents complements Beacon’s existing suite of therapeutic area databases and currently extends to Beacon ADC, but will expand to Beacon Bispecific and Beacon Oncology soon. Our patents data is built around the same principles of scientific curation, data integrity, and usability.

As with other Beacon products, Beacon Patents will continue to evolve, with planned enhancements including deeper commercial patent metrics, integration with drug and trial data, and expanded coverage.

Find out more or request a demonstration for Beacon ADC Patents today!

Beacon Intelligence has expanded its oncology offering with the launch of Beacon Oncology: Deals and Companies, a new dataset that provides extensive commercial insight into the oncology drug development sector.

Developed in response to the increasing complexity of the commercial oncology market, this latest addition delivers structured and searchable data on over 15,500 oncology-related deals and 8,500 companies, enabling users to make faster, more strategic decisions across R&D, business development, and competitive intelligence functions.

Comprehensive Commercial Intelligence for the Oncology Sector

The Deals and Companies dataset gives subscribers access to curated information on mergers and acquisitions (M&A), licensing agreements, collaborations, partnerships, and funding rounds, alongside detailed company profiles spanning the oncology drug development space.

This dataset expansion is designed to work alongside Beacon’s scientific and clinical trial intelligence to give users a holistic view of the oncology landscape, from research and development through to strategic business activity.

“With this latest dataset, we’re offering our users a new lens through which to view the oncology space—one that brings commercial activity into sharper focus,” said Kieran Pinto, Senior Researcher at Beacon Oncology. “Whether you’re looking to identify potential partners, benchmark licensing deals, or monitor competitors, Beacon Oncology: Deals and Companies delivers the intelligence you need to act quickly and confidently.”

Helping Pharmaceutical and Biotech Professionals Make Smarter Commercial Decisions

With deal-making continuing to play a critical role in oncology innovation, the ability to track and analyse commercial activity in real time is increasingly valuable. Beacon’s new dataset allows users to:

• Identify acquisition and investment opportunities with access to a broad and deep pool of deal data
• Evaluate and shortlist potential partners based on company size, therapeutic focus, pipeline stage and more
• Benchmark licensing and M&A deals to support more informed and competitive negotiations
• Monitor competitor activity and development strategy in real time through structured, up-to-date data

The dataset expansion covers both public and private deals, with intelligence spanning preclinical research through to commercialisation. All entries are manually curated by Beacon’s in-house analysts to ensure accuracy and relevance.

Built for Commercial, Corporate Development and Business Development Teams

Designed to meet the needs of commercial strategy, business development, and corporate development teams, Beacon Oncology: Deals and Companies enables cross-functional collaboration by aligning market intelligence with R&D strategy.

Its intuitive interface and advanced filtering tools mean users can quickly narrow down to relevant datasets, whether they’re screening for out-licensing partners or comparing deal terms by indication, modality or geography.

The dataset expansion also includes company intelligence pages, providing a single view of a company’s oncology-related activity, partnerships, and pipeline assets. This feature streamlines partner evaluation and helps commercial teams track competitor movement with precision.

Real-Time Intelligence Backed by Beacon’s Proven Platform

The Deals and Companies dataset is built on the same robust platform as Beacon’s scientific and clinical trial databases. That means users benefit from:

• A unified search experience across all oncology data types
• Consistent data standards and ontologies for accurate comparisons
• Regular updates and expert curation to maintain data accuracy
• A trusted platform already used by hundreds of pharma and biotech teams globally

This launch marks a significant step forward in Beacon’s mission to support smarter, faster oncology drug development by providing end-to-end insight.

Enhancing Decision-Making Across the Oncology Sector

Beacon’s expanded Oncology offering now spans scientific, clinical, and commercial intelligence, offering one of the most comprehensive oncology data ecosystems available. By integrating Deals and Companies with existing datasets, users can:

• Track how scientific innovations translate into commercial outcomes
• Identify strategic gaps and opportunities across the market
• Build more robust development and licensing strategies based on evidence
• Stay agile in a competitive and rapidly evolving field

Kieran Pinto, Senior Researcher at Beacon Oncology adds: “What sets Beacon apart is our ability to deliver integrated, high-quality datasets that support smarter decisions across the drug development lifecycle. Deals and Companies is the next evolution of that vision, and we’re excited to see how our clients use it to accelerate their commercial strategies.”

Find out more about Beacon Oncology

Beacon has launched Beacon Oncology, a comprehensive database designed to support oncology drug development scientists working at biotech and pharmaceutical companies across the world.

With access to 25,000+ drugs and 50,000+ clinical trials, Beacon Oncology is the most complete oncology database in the world, offering unprecedented insights into the complex landscape of oncology research and development.

Supporting Drug Development Scientists in the Fight to Develop Effective Drugs Efficiently.

In an era where the competition in oncology drug development is at an all-time high, the need for accurate, comprehensive, and timely data has never been greater. The probability of successfully bringing an oncology drug to market is estimated to be less than 4%, making strategic decision-making crucial for R&D success.

Through its database, Beacon is addressing this challenge by equipping scientists with curated, structured, and highly searchable data that enables them to:

• Identify emerging trends in oncology drug development
• Track competitor activity and benchmarking progress
• Optimize drug development strategies with robust clinical trial insights
• Reduce time spent on data collection and analysis
• Make informed decisions faster, improving the likelihood of success

By providing visibility into the oncology landscape across all drug modalities, Beacon Oncology empowers scientists to navigate the complexities of drug discovery and development with confidence.

Data from Early-Stage Research to Late-Phase Clinical Trials

Beacon Oncology is built on an advanced, user-friendly platform that consolidates oncology drug development data from early-stage research to late-phase clinical trials. The database offers:

• Unparalleled Data Accuracy – Derived from proprietary technologies and expert curation, ensuring the highest level of reliability.
• Comprehensive Coverage – Providing 20% more drugs and trials than the nearest competitor.
• Modality-Specific Ontologies – Enabling precise insights across the oncology treatment landscape.
• Structured and Searchable Content – Offering over 30 filters to refine searches and analyze data effectively.
• Manually Curated Data – Verified by experts for enhanced accuracy and success.

The database is updated daily, ensuring that users have access to the latest information on drugs and clinical trials in real time.

A Strategic Intelligence Tool designed to Accelerate Innovation and Improve Success Rates

Beacon Oncology is more than just a database. It is a strategic intelligence tool designed to accelerate innovation and improve success rates in oncology drug development. Key benefits include:

1. Enhanced Drug Development Strategy

Scientists can leverage Beacon Oncology’s comprehensive dataset to refine their research and prioritize the most promising drug candidates based on competitive insights and clinical trial outcomes.

2. Accelerated R&D Decision-Making

By offering structured and highly searchable data, Beacon Oncology reduces the time spent on research, allowing scientists to focus on groundbreaking discoveries and optimizing drug development timelines.

3. Competitive Advantage in Oncology Research

With up-to-date and curated intelligence, researchers can stay ahead of market trends, monitor competitor activities, and adapt their strategies accordingly to gain a competitive edge.

4. Increased Success Rates in Clinical Trials

Access to real-time clinical trial data enables scientists to identify the most effective trial designs and avoid potential pitfalls, thereby increasing the probability of successful drug approval.

5. Seamless Integration into Existing Workflows

Beacon Oncology is designed to integrate smoothly into existing research and development workflows, offering a user-friendly interface and powerful analytical tools to enhance productivity and collaboration.

Jake Morris, Account Manager at Beacon comments: “Beacon Oncology is set to revolutionize how scientists approach oncology drug development. By providing access to the most comprehensive dataset available, we’re enabling researchers to make more informed decisions faster, ultimately accelerating the path to breakthrough treatments. This is a major step forward for Beacon and for the entire oncology community.”

Find out more about Beacon Oncology

The publication provides an in-depth analysis of RNA drug development, highlighting the expansion of various RNA classes and the rapid growth of the mRNA pipeline across multiple therapeutic areas. A key part of the study was supported by data obtained from Beacon Intelligence, which provided insights into the number of programs by RNA class and the therapeutic distribution of the mRNA pipeline.

RNA therapeutics have emerged as one of the most promising areas in modern medicine, with applications spanning oncology, rare diseases, infectious diseases, and more. The rise of mRNA-based treatments, particularly in response to the COVID-19 pandemic, has demonstrated the immense potential of RNA platforms to address a wide range of medical conditions.

The Nature article emphasizes the importance of accurate and comprehensive data in tracking and analyzing the evolution of these therapies, a gap that Beacon RNA fills with its industry-leading intelligence platform. Beacon Intelligence supplied this exclusive data through its RNA dataset using the ‘Drug Data’ view.

Ioana Panait, Senior Lead Research Analyst, at Beacon Intelligence comments: “Being cited in Nature highlights the value and impact of Beacon’s comprehensive RNA dataset. Researchers and industry leaders rely on our data to navigate the complexities of RNA therapeutics, accelerating the development of ground-breaking treatments. This acknowledgment reinforces our commitment to providing industry-leading intelligence for the scientific community.”

Beacon Intelligence’s RNA dataset is meticulously curated by a team of expert analysts who continuously monitor industry developments, clinical trials, and emerging trends in RNA-based drug development. This ensures that subscribers to Beacon RNA have access to the latest intelligence, enabling them to make informed strategic decisions in drug discovery and development.

In addition to RNA therapeutics, Beacon Intelligence provides datasets covering a broad spectrum of complex drug modalities, including Antibody Drug-Conjugates (ADCs), Cell Therapies, Gene Therapies and Bispecifics. This comprehensive approach positions Beacon Intelligence as a key resource for biotech and pharmaceutical companies, investors, and researchers seeking to understand the evolving drug development landscape.

The citation in Nature further solidifies Beacon RNA’s reputation as a trusted source of high-quality intelligence. By offering granular data on RNA therapeutic development, including pipeline distribution, preclinical and clinical trial progress, and competitive intelligence, Beacon Intelligence plays a vital role in supporting innovation and accelerating the translation of RNA research into real-world treatments.

What is Beacon RNA?

Beacon RNA is the most comprehensive RNA therapeutics database available. Providing timely and accurate, market leading, pre-clinical and clinical RNA drug, trial, and commercial intelligence data.

• Unrivalled comprehensive & accurate pre-clinical and clinical RNA therapeutic drug, trial and commercial data.
• Access to >4,500 Drugs, >2,000 Trials, >2,500 Companies, and >2,500 Deals in the RNA Therapeutic space
• Market leading ontologies, enabling precise navigation of specific RNA therapeutics
• Manually curated by RNA scientists, with data updated daily
• Your one stop shop for RNA therapeutic intelligence data

Learn More About Beacon RNA

Immune Tolerance Deals and Companies Dataset.

In February, Beacon Immune Tolerance saw the rollout of its Deals and Companies dataset—adding critical business development intelligence to its already robust scientific data. This addition supports users in sourcing strategic partnerships, benchmarking deal structures, and conducting due diligence on potential collaborators. Whether identifying M&A targets, monitoring the competitive landscape, or evaluating commercial potential, this dataset equips our clients with insights needed to guide informed, strategic decisions​.

Global Trial Locations

In August, Beacon enhanced all datasets with the introduction of Clinical Trial Location Data. This update helps users make strategic decisions around patient recruitment and competitor analysis. By visualizing where trials are being conducted globally, users can identify underutilised regions for recruitment and gain intelligence into the geographic spread of competitor activity, both at a local and global level​.

Beacon Oncology Launch

September marked the launch of Beacon Oncology, our most ambitious dataset to date. Developed from a disease-specific lens this module now provides access to more than 25,000 oncology drugs and 50,000 trials, surpassing competing databases by at least 20% in volume, while maintaining over 95% data accuracy.

Due to its in-depth suite of search filters, Beacon Oncology allows users to investigate drugs and trials across oncology subtypes and modalities, from preclinical to late-stage development. This integrated perspective enables faster decision-making in an increasingly complex oncology landscape and paves the way for additional disease-focused Beacon modules in the future​.

Expanding into Atopic Dermatitis

In October, Beacon expanded its Immune Tolerance dataset with a comprehensive new focus on Atopic Dermatitis (AD). This enhancement includes over 590 drugs and more than 800 clinical trials, with a significant portion already in the clinic. The update also brings coverage of cutting-edge innovations such as JAK inhibitors and IL-13 targeting biologics. The depth and focus of the dataset—alongside curated, immune-specific ontologies—make it a powerful tool for researchers navigating the fast-evolving AD space​.

Oncology Trial Locations and Milestones

By December, Beacon Oncology users gained access to new Trial Location and Milestones data, allowing for deeper visibility into site selection and trial progress. With the Milestones filter and new visualizations, users can now track key clinical and regulatory readouts, identify trial locations, and map drug development timelines with greater clarity. These additions support more efficient competitive intelligence gathering and better-informed trial planning strategies​.

Looking Ahead to 2025

Beacon is building on its 2024 successes with significant plans for 2025:

• UX/UI Upgrade: A redesigned user interface will streamline the research journey. A new homepage, enhanced result lists, and personalized content will make it easier than ever to find and act on the most relevant data.
• API Integration: The upcoming launch of APIs will allow users to pull Beacon data directly into internal systems—empowering scientific, commercial, and strategic teams with seamless, real-time intelligence.
• Beacon Oncology: Deals and Companies: In early 2025, our clients will be able to access company profiles and deal activity within Beacon Oncology, offering greater visibility into commercial strategy and partnership landscapes.
• Patent Dataset Launch: A new patent search tool will allow users to understand intellectual property trends, strengthening strategic planning in discovery and development.

We believe that these enhancements will further Beacon’s mission to become the intelligence partner of choice for the pharmaceutical and biotech industry, with data tools that support every step of the drug development process.

The publication provides an in-depth analysis of ADCs, a rapidly growing class of targeted cancer therapies. Researchers relied on Beacon Intelligence’s ADC dataset to assess the current development pipeline, analyze clinical progress, and map emerging trends in ADC technology. The study emphasizes the increasing interest in ADCs as a promising therapeutic modality, with significant advancements in linker chemistry, payload mechanisms, and targeted delivery systems.

ADCs represent a ground-breaking approach in oncology, combining the precision of monoclonal antibodies with the potent cytotoxicity of small-molecule drugs. This innovative strategy enables highly selective tumor targeting while minimizing damage to healthy tissues. The mAbs publication underscores the importance of reliable, high-quality data in tracking the evolution of ADC therapeutics, an area where Beacon Intelligence provides unparalleled insights.

Beacon Intelligence’s ADC dataset offers comprehensive coverage of preclinical and clinical-stage ADC programs worldwide. Curated by expert analysts, the platform delivers real-time intelligence on pipeline developments, clinical trial outcomes, and regulatory progress. The dataset is available through Beacon Intelligence’s subscription service, allowing biotech and pharmaceutical companies, as well as academic institutions, to make data-driven decisions in ADC research and development.

Yu-Shin Hsu, Lead Research Analyst, at Beacon Intelligence comments: “Being cited in mAbs reinforces the impact of Beacon ADC’s dataset in supporting ground-breaking research. Our goal is to provide the most accurate and up-to-date intelligence, enabling researchers and industry leaders to navigate the rapidly evolving ADC landscape with confidence.”

What is Beacon ADC?

Beacon ADC is the most comprehensive Antibody-Drug Conjugate (ADC) database available. Providing timely and accurate, market leading, pre-clinical and clinical drug, trial, and commercial intelligence data.

• The Most Comprehensive Way to Search the ADC Drug Development Landscape: Unique search ontologies based on ADC drug and trial characteristics
• Market Leading Approach to ADC Preclinical & Clinical Data Curation: Manual curation of key ADC research and development data points by ADC research scientists
• Seamlessly Integrate Commercial & Scientific Data all in One Place: Search ADC company and deal data based on their pipeline and technologies.
• Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.

The fight to improve outcomes for patients with immune mediated-diseases has taken a step forward following the publication of Beacon Intelligence’s Immune Tolerance Dataset. The dataset covers all pharmaceutical interventions used to treat autoimmune diseases, autoinflammatory diseases, alloimmune diseases and allergies.

Designed specifically to equip drug development scientists with crucial information to further their work, the Immune Tolerance Dataset provides unparalleled insights into the growing landscape of autoimmune therapies, helping researchers make faster and more informed decisions.

An Essential Resource for Drug Development Scientists

The Immune Tolerance Dataset is an essential resource that allows drug developers to track and analyze the latest advancements in therapies targeting immune-mediated diseases.

With more than 6,000 drugs (including over 2,400 clinically active and 1,400 that are in active pre-clinical development) and 12,000 clinical trials meticulously cataloged, Beacon’s dataset serves as the most comprehensive tool available to benchmark assets, analyze competitive landscapes, and stay up to date with the latest scientific breakthroughs.

Bella Glover, Immune Tolerance Research Analyst at Beacon comments: “We are committed to providing researchers with the most accurate and actionable data available so we can drive forward better outcomes for patients globally. With the launch of our Immune Tolerance Dataset, we are equipping drug development scientists with the resources they need to develop effective therapies efficiently, saving time and money.”

The Immune Tolerance Dataset

The dataset provides comprehensive coverage of all therapies treating autoimmune diseases, autoinflammatory diseases, alloimmune diseases and allergies including immunomodulators, immunostimulants, immunosuppressives and immune tolerance therapeutics.

Some of its key features include:

• 6,000+ drugs, with 2,400+ in clinical development and 1,400+ in active preclinical development
• 12,000+ trials, including 900+ active but not recruiting
• 5,000+ developers engaged in immune-mediated disease research
• In-depth categorization of drugs based on mechanism of action, autoantigen specificity, cell source, delivery system, and formulation
• Rapid updates, ensuring the most current data is always available

Importantly, the dataset also includes a commercial intelligence and data expansion. This gives researchers unparalleled access to in-depth company profiles and the latest commercial deals, enabling them to monitor competitors and opportunities as well as evaluating potential partners.

How does the Immune Tolerance Dataset Work?

Beacon’s analytical tools, milestones filter and visualization technology make it easier than ever to navigate the complex immune tolerance research landscape. The platform provides detailed filters and data fields tailored to the needs of scientists, allowing them to:

• Track new developments in autoimmune, autoinflammatory, alloimmune diseases, and allergies
• Compare their pipeline assets against competitors in real time
• Identify emerging trends in drug development and clinical trials
• Make evidence-based strategic decisions with confidence

These data fields include:

• Autoantigen Specificity
• Mechanism of Action
• Cell Source
• Cell Type
• Delivery System
• Editing Technology
• Target Organ/Cell
• Formulation

Accelerating Immune Tolerance Development Programs

The Immune Tolerance dataset benefits Beacon’s clients by accelerating their immune tolerance development programmes. It enables scientists to:

• Search therapeutics in the immune-disease space across all stages of development so you can accurately benchmark your strategies against all existing immune tolerance and immunomodulatory drugs, and investigate the novel technologies being used by competitors
• Drastically reduce manual research time spent looking through publications and conference abstracts for preclinical and clinical trial results by relying on our comprehensive collection of data which can be searched by a variety of options including delivery system, cell type, disease indications and much more.
• Stay on top of emerging trends and new players in the immune tolerance field with real-time updates and alerts, as well as in-depth monthly reports curated by our analyst team.

Bella Glover adds: “The immune tolerance landscape is evolving quickly, and it is therefore crucial for scientists to have access to accurate data. Generic databases often fail to provide the depth of insight needed for highly specialised fields such as immune tolerance research. Beacon’s Immune Tolerance Dataset fills this critical gap by offering a highly curated, niche focused solution designed to meet the needs of scientists working in this area.

Having access to detailed and up-to-date information can make the difference to a new therapy being developed successfully or not. This dataset not only enhances our clients’ ability to track and analyze immune tolerance therapies but also helps them accelerate drug development, optimize clinical strategies, and ultimately improve patient outcomes.”

Find out More about our Immune Tolerance Database